Compare DV & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DV | AUPH |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2021 | 1999 |
| Metric | DV | AUPH |
|---|---|---|
| Price | $11.50 | $16.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 4 |
| Target Price | $16.56 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.26 | ★ 0.55 |
| Revenue | ★ $733,324,000.00 | $265,808,000.00 |
| Revenue This Year | $17.93 | $21.76 |
| Revenue Next Year | $10.61 | $16.45 |
| P/E Ratio | $43.73 | ★ $29.54 |
| Revenue Growth | 14.86 | ★ 20.62 |
| 52 Week Low | $7.64 | $6.55 |
| 52 Week High | $23.11 | $16.54 |
| Indicator | DV | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 63.13 |
| Support Level | $11.15 | $16.00 |
| Resistance Level | $11.48 | $16.54 |
| Average True Range (ATR) | 0.28 | 0.41 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 83.98 | 80.58 |
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.